SNDX
Syndax Pharmaceuticals Inc
18.00$
+1.9%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 100.0% | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | 50.0% | – | 1,266.8% | 0.0% | 10.8% | 4.4% | 3.4% | 4.6% | -2.3% | 4.1% | 4.4% | 2.5% | |
| – | 50.0% | – | 100.0% | 100.0% | 100.0% | 95.6% | 96.6% | 95.4% | 102.3% | 95.9% | 95.6% | 97.5% | |
| – | 10,284.7% | – | 1,390.1% | 567.8% | 853.2% | 307.5% | 163.9% | 122.7% | 114.8% | 90.7% | 93.5% | 103.9% | |
| – | 8,235.6% | – | 830.3% | 248.8% | 490.8% | 204.7% | 115.4% | 97.9% | 72.9% | 57.9% | 57.1% | 69.0% | |
| – | 14,534.5% | – | 2,220.5% | 816.6% | 1,354.8% | 513.5% | 279.3% | 220.6% | 193.6% | 148.7% | 150.5% | 174.5% | |
| – | -14,534.5% | – | -2,120.5% | -716.6% | -1,254.8% | -417.9% | -182.7% | -125.2% | -91.3% | -52.7% | -54.9% | -77.1% | |
| – | 11.8% | – | 1.3% | 0.2% | 62.6% | 40.2% | 20.7% | 18.1% | 77.0% | 18.3% | 17.4% | 33.9% | |
| – | -13,521.1% | – | -1,944.7% | -673.0% | -1,226.2% | -423.3% | -189.3% | -132.4% | -99.3% | -65.8% | -67.8% | -87.6% | |
| – | 931.5% | – | – | 0.0% | – | – | – | – | – | – | – | – | |
| – | -13,521.1% | – | -1,944.7% | -673.0% | -1,226.2% | -423.3% | -189.3% | -132.4% | -99.3% | -65.8% | -67.8% | -87.6% | |
| – | -13,508.8% | – | -1,943.3% | -672.8% | -1,163.6% | -417.9% | -168.4% | -114.3% | -22.4% | -47.5% | -50.4% | -53.7% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.